In their response to the House Budget Committee’s request, the Partnership for Protecting Coverage outlined three overarching principles to guide health care reform and improve the U.S. health care system.
Site Search
Partnership for Protecting Coverage statement is in response to a hearing entitled “Reduced Care for Patients: Fallout from Flawed Implementation of the Surprise Medical Bill Protections.”
In feedback provided to the U.S.
The Cystic Fibrosis Foundation joined an ad hoc coalition of stakeholders in calling for strong support of newborn screening programs as Congress continues ongoing negotiations for the Fiscal Year 2024 Labor, Health and Human Services, and Education Appropriations bill.
The Cystic Fibrosis Foundation sent a letter to the Texas Insurance Commission requesting clarity on which insurance plans are impacted by HB99, which requires insurers to apply third-party assistance to out-of-pocket maximums and other cost-sharing requirements.
The CF Foundation expressed support to the Council of the District of Columbia for B25-0124, Prior Authorization Reform Amendment Act of 2023, which makes several important reforms to the prior authorization process.
An ad hoc coalition of patient advocacy organizations sends a letter to Governor DeSantis asking the state to address the redetermination process and the unnecessary loss of coverage for children.
The CF Foundation sent a letter of support to Ohio’s Public Health Policy Committee supporting House Bill 177, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
In a letter to the state’s Department of Human Services, the Foundation supported Pennsylvania’s request to change provisions of its Medicaid program, including continuous eligibility for children under 6 and services for health-related social needs.
The Cystic Fibrosis Foundation provided comments to the Patient Centered Outcomes Research Institute on their draft landscape of patient-centered economic outcomes that provides recommendations to researchers seeking to understand the economic impacts of living with a disease.